kelly physical therapy, pLLC

92 horatio st apt 4p
new york, new york 10014

NYS Entity Status
ACTIVE

NYS Filing Date
SEPTEMBER 30, 2013

NYS DOS ID#
4465901

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC PROFESSIONAL SERVICE LIMITED LIABILITY COMPANY

Name History
2013 - KELLY PHYSICAL THERAPY, PLLC









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Stealthy NY Startup Rocket Pharma Merges With Inotek, Heads to Nasdaq
    By Ben Fidler - Tuesday Sep 12, 2017

    Rocket Pharmaceuticals, a stealthy gene therapy startup in New York City, has made its first splash. Through a merger with struggling Inotek Pharmaceuticals (NASDAQ: ITEK), Rocket, a company developing treatments for a variety of rare blood diseases, has taken itself public. Rocket shareholders are expected to own 81 percent of the combined company, with Inotek […]

    Source: Xconomy New York
  • The Rebuilding Years, Post-Sandy
    By THE NEW YORK TIMES and JONAH MARKOWITZ - Sunday Oct 29, 2017

    Those affected by Hurricane Sandy five years ago shared how the storm changed their lives physically, emotionally and financially, and how things have changed for the better since.

    Source: NYT > Home Page
  • 15 November, 2017 – Episode 645 – This Week in Science (TWIS) Podcast
    By Kirsten Sanford - Thursday Nov 16, 2017

    Interview w/ Kelly Weinersmith, Noisy Feathers, Smelly Feathers, Wine Time, Climatia Update, Neolithic Farmer Gatherers, Pulsar Pulse, Zinc Finger Treatment, Sex Attacks, And Much More...

    Source: This Week in Science
  • FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
    By Ben Fidler - Tuesday Aug 29, 2017

    The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]

    Source: Xconomy New York
  • Acorda Scraps One Parkinson’s Drug, Puts Its Cash Behind Another
    By Frank Vinluan - Monday Nov 20, 2017

    Acorda Therapeutics said Monday that it will stop work on an experimental treatment for Parkinson’s disease, spelling the end for a drug the Ardsley, NY, company added to its pipeline last year in a $363 million deal. The announcement follows the recent emergence of safety problems for the Acorda (NASDAQ: ACOR) drug, tozadenant. Acorda said […]

    Source: Xconomy New York